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Abstract
Harnessing the ability of cytotoxic T lymphocytes (CTLs) to recognize and eradicate tumor or pathogen-infected cells is a
critical goal of modern immune-based therapies. Although multiple immunization strategies efficiently induce high levels of
antigen-specific CTLs, the initial increase is typically followed by a rapid contraction phase resulting in a sharp decline in the
frequency of functional CTLs. We describe a novel approach to immunotherapy based on a transplantation of low numbers
of antigen-expressing hematopoietic stem cells (HSCs) following nonmyeloablative or partially myeloablative conditioning.
Continuous antigen presentation by a limited number of differentiated transgenic hematopoietic cells results in an
induction and prolonged maintenance of fully functional effector T cell responses in a mouse model. Recipient animals
display high levels of antigen-specific CTLs four months following transplantation in contrast to dendritic cell-immunized
animals in which the response typically declines at 4–6 weeks post-immunization. Majority of HSC-induced antigen-specific
CD8
+ T cells display central memory phenotype, efficiently kill target cells in vivo, and protect recipients against tumor
growth in a preventive setting. Furthermore, we confirm previously published observation that high level engraftment of
antigen-expressing HSCs following myeloablative conditioning results in tolerance and an absence of specific cytotoxic
activity in vivo. In conclusion, the data presented here supports potential application of immunization by limited
transplantation of antigen-expressing HSCs for the prevention and treatment of cancer and therapeutic immunization of
chronic infectious diseases such as HIV-1/AIDS.
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Introduction
CTLs play a key role in the immune-mediated control of cancer
and various infectious diseases. However, endogenous antigen-
specific effector T cells induced by transformed cells or invading
pathogens are continually depleted by processes of functional
exhaustion, anergy, and activation-induced cell death [1–5].
Multiple clinical trials have demonstrated that the administration
of autologous dendritic cells (DCs) presenting tumor-specific
antigens represents a highly effective method of eliciting tumor-
specific CTLs. However, this strategy appears to have limited
therapeutic effect due to the limited longevity and migratory
capacity of injected DCs [6–10]. Similarly, adoptive transfer of ex
vivo-expanded autologous tumor antigen-specific CTLs for cancer
immunotherapy is restricted by the fact that expanded T cells
display limited survival upon transfer to recipients and long-lasting
remissions are observed only in a fraction of patients [1,11]. In
chronic viral infections such as human immunodeficiency virus-1
(HIV-1) infections in humans or simian immunodeficiency virus
(SIV) infection in macaques, we and others have shown that
therapeutic immunization of infected animals with recombinant
viral vaccines inducing cellular responses improves their ability to
control infection in the absence of anti-retroviral therapy;
however, vaccine-induced antigen-specific CTLs rapidly decline
to pre-immunization levels within weeks post immunization [3,12–
14]. The transient nature of vaccine-induced immune responses
represents an important problem in the fields of vaccinology,
immunotherapy of cancer, and immunotherapy of HIV-1/AIDS.
New strategies improving long-term maintenance of functional
CTLs are critically needed for an efficient immunotherapy of
cancer and chronic infectious diseases.
The potential of genetically modified HSCs to sustain multi-
lineage reconstitution in autologous or heterologous hosts resulting
in corrections of various diseases has been well demonstrated [15–
19]. The pluripotent nature of HSCs allows them to differentiate
into multiple cell lineages including professional antigen presenting
cells (APCs). Mobilized human CD34
+ HSCs can be isolated in
large numbers and genetically modified by transduction with
lentiviral vectors encoding the genes of interest under a control of
a target lineage-specific promoter. Importantly, recent advances in
the design of self-inactivating lentiviral vectors resulted in a
significant increase in the safety of lentivirally-modified HSCs and
spurred a number of newly initiated clinical trials [17–19]. Several
previously published reports have addressed potential application
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16897of immunization with genetically modified HSCs [20–22].
However, measurable immune responses and control of tumor
growth were achieved only by adopting complex protocols
involving adoptive transfer of antigen-specific transgenic T cells
and co-administration of anti-CD40, Flt3, GMCSF and/or CpG.
In this report we investigate a novel approach to long-term
elicitation of CD8
+ T cells in vivo based on a limited
transplantation of genetically modified autologous HSCs resulting
in a continually renewing reservoir of cells presenting and/or
cross-presenting the antigen. This would result in a reduction of
the number of administrations of cellular vaccines needed for long-
term maintenance of antigen-specific responses. We demonstrate
that induction of a limited antigenic microchimerism by
transplantation of low numbers of genetically modified HSCs in
combination with nonmyeloablative conditioning results in an
expansion of antigen-specific T cells displaying central memory
phenotype and providing prolonged protective CTL responses. In
contrast, high-level transplantation of antigen-expressing HSCs
into fully myeloablated recipients results in an induction of T cell
anergy and absence of antigen-specific target cell killing in vivo.
Materials and Methods
Ethics Statement
All experimental procedures were approved by the Institutional
Animal Care and Use Committee at the University of Alabama at
Birmingham (approval number 071207243 and 070507485).
Mice
C57Bl/6 (B6) and SJL mice were obtained from Harlan
Laboratories (Indianapolis, IN); OVA-transgenic mice expressing
chicken OVA under the control of chicken b-actin promoter/
CMV immediate-early enhancer were obtained from Jackson Labs
(Bar Harbor, ME; strain # 005145).
Isolation and transplantation of HSCs
Bone marrow cells were harvested from the radius, tibias,
femurs, and humerus of donor animals and resuspended in
complete RPMI medium (RPMI-1640, 0.3 mg/ml L-glutamine,
100 U/ml penicillin, 100 U/ml streptomycin, 50 mM 2-mercap-
toethanol [Invitrogen, Carlsbad, CA] supplemented with 10%
heat-inactivated fetal bovine serum [FBS, Cellgro, Mediatech Inc,
Manassas, VA]). Bone marrow cells were filtered through a 70 mm
Nylon mesh (Falcon, Franklin Lakes, NJ) and erythrocytes were
lysed in RBC Lysis Buffer (Biolegend, San Diego, CA). Lineage
negative (Lin
2) cells were enriched from bone marrow cells using
the Lineage Cell Depletion kit (Miltenyi Biotec, Auburn, CA) and
stained with anti-Sca-1 and c-kit antibodies (BD Biosciences, San
Jose, CA). Lin
2 Sca-1
+ c-kit
+ (LSK) cell population was sorted on
a FACSVantage (BD Bioscience). Typically, 6-7610
4 LSK cells
were isolated from each 6–8 week old female B6 mouse.
Two days prior to transplantation, mice were pretreated with
60 mg/kg busulfan (BU; Sigma, St. Louis, MO) in 300 ml PBS
administered I.P. Nonmyeloablative dose of BU selectively kills
HSCs thus making stem-cell niches available for the engraftment
of donor HSCs [23,24]. Alternatively, a single dose of radiation
was administered at the indicated amount on the day of
transplantation. In experiments involving administration of 900
RADs, the total time of exposure was split into two with a 10
minute rest period in between. Irradiated mice received 1.1 g/L of
neomycin sulfate (Mediatech Inc., Manassas, VA) in drinking
water two days prior to irradiation and for two weeks post-
irradiation. 500 - 2610
4 cells were injected intravenously (i.v.) into
the lateral tail vein of the recipient animal.
DC Immunization
Bone marrow-derived dendritic cells were prepared from
harvested bone marrow cells by 8 day incubation in the presence
of 20 ng/ml GM-CSF (R&D systems, Minneapolis, MN) as
previously described [25]. Mice were immunized by i.v. or foot
pad injection with indicated numbers of DCs derived from OVA-
transgenic mice (DC-tOVA) or DCs from B6 mice coated for 2 hrs
with 10 mM of OVA-1 and OVA-2 peptides in complete RPMI
medium (DC-pOVA). MHC class I-restricted OVA-1 (OVA257–
264, SIINFEKL) and MHC class II-restricted OVA-2 (OVA323–
339, ISQAVHAAHAEINEAGR) peptides were synthesized by
Genemed Synthesis (South Francisco, CA).
To assess the relative contribution of various hematopoietic
lineages to the induction of antigen-specific CD8
+ T cells in HSC-
immunized recipients, individualcellpopulations werepurified from
OVA-transgenic mice. B cells and DCs were sequentially purified
from homogenized spleen and lymph node cells using CD19
+ and
CD11c
+ MicroBeads kits and MACS columns (Miltenyi Biotec).
The CD19
2CD11c
2 cell fraction was then stained with anti-CD3,
CD49andCD11bantibodies(BDBiosciences)andsortedintoTcell
(CD3
+), NK cell (CD3
2CD49
+), macrophage/monocytes
(CD3
2CD49
2CD11b
+), and other (CD3
2 CD49
2 CD11b
2)c e l l
populations using FACSAria cell sorting system (BD). Cell
populations were collected in complete RPMI 1640, washed, and
resuspended in RPMI1640 without additives. 2610
4 cells of each
population were injected i.v. into the tail vein of recipient animals.
Pentamer and cell surface marker staining
Following erythrocyte lysis, splenocytes homogenized into a
single cell suspension or peripheral blood mononuclear cells
(PBMCs) were incubated with PE-conjugated OVA-1-specific
MHC-I pentamer (ProImmune, Springfiled, VA) for 40 min at
4uC. Cells were washed and stained with anti-CD8 (BD), CD62L,
CD27, or CD127 (eBiosciences, San Diego, CA) antibodies for
additional 20 min at 4uC prior to washing and flow cytometry
analysis (FACSCalibur, BD). In experiments where SJL (CD45.1
+)
and B6 (CD45.2
+) were used as donors and recipients, respectively,
the level of engraftment was determined by collecting 100 mlo f
blood from the tail vein and staining the obtained PBMCs with
CD45.1 and CD45.2 antibodies (BD) for 20 min at 4uC.
In vivo cytotoxic T cell assay
10
7 autologous splenocytes from wild-type B6 mice were labeled
using 0.35 mM 5-(and 6)-carboxyfluorescein diacetate succinimidyl
ester (CFSE; control population) and 10
7 autologous splenocytes
from OVA-transgenic mice were labeled using 3.5 mM CFSE
(target population) according to the manufacturer’s protocol
(Invitrogen). Both populations were simultaneously administered
i.v. into the tail vein. Under these conditions, only splenocytes from
OVA-transgenic mice (high intensity peak on the right) will be
recognized by recipient’s OVA-specific CTLs. Spleens of immu-
nized and control animals were harvested 24 hrs later, homoge-
nized into single cell suspensions, red blood cells were lysed and
target cell killing was determined by flow cytometry analysis
(FACSCalibur,BD). Relativekillingratio was calculatedbydividing
CFSE High/Low ratio in individual treated animals by the average
ratio observed in untreated control animals; the values subtracted
from 100% represent the percentage of target cells killed.
Tumor protection assay
16 weeks post-HSC injection, mice were inoculated subcutane-
ously in left flank with 10
6 thymoma-derived E.G7 cells expressing
OVA [26]. Tumor size was monitored every two days by
HSCs Induce Prolonged Cytotoxic T Cell Responses
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was calculated using the formula: (width)
2 6length.
Statistical Analysis
All reported P values are two-sided. Group comparisons were
performed using the Mann-Whitney rank sum test and repeated-
measures ANOVA (RM-ANOVA). Correlations were performed
using Spearman rank order test. The SigmaStat (SPSS, Chicago,
IL) and GraphPad Prism (GraphPad Software Inc., LaJolla, CA)
statistical and graphing software packages were used.
Results
Transplantation of genetically modified HSCs results in
an improved longevity of vaccine-induced antigen-
specific CD8
+ T cell responses
To address whether sustained low-level expression of antigen
results in an induction and maintenance of antigen-specific CTLs,
recipient C57Bl/6 (B6) mice were transplanted with HSCs from
OVA-transgenic donor mice on B6 background (HSC-tOVA).
Two days prior transplantation, recipient animals were non-
myeloablatively conditioned with busulfan (BU; 60 mg/kg i.v.)
[23,24]. HSC recipients were injected i.v. with a single dose of 500
or 2610
4 of HSC-tOVA. Control groups were injected i.v. with
10
5 DCs derived from OVA-transgenic donors (DC-tOVA). The
frequency of OVA-specific CD8
+ T cells in DC-immunized mice
peaked at 1 week after immunization and rapidly declined
thereafter (Fig. 1A, left). In contrast, in HSC-tOVA-immunized
mice, OVA-specific CD8
+ T cells appeared with slower kinetics
reaching high frequencies at weak 4 post transplantation (Fig. 1A,
B). This is consistent with the appearance of circulating donor cells
at 3–4 weeks post transplantation as evidenced by the occurrence
of chimerism in CD45.2
+ controls transplanted with CD45.1
+
Lin
2 Sca-1
+ HSCs (Fig. 2B and data not shown) [22].
Considerable variations in the frequencies of antigen-specific
CD8
+ T cells were observed among individual animals (Fig. 1A). A
significant decrease in the frequency of antigen-specific T cells
consistently occurred at 8 weeks post HSC transplantation
followed by an increase at 12 weeks. This phenomenon is
consistent with differences in the kinetics of appearance of cells
descending from long-term self-renewing pluripotent HSCs versus
short-term HSCs and partially differentiated lineage-committed
common myeloid and lymphoid progenitors [22,27–30]. The
increase in the frequency of antigen-specific cells at 12 weeks
suggests continuous low-level antigen expression. High levels of
OVA-specific T cells were detectable at 16 weeks post vaccination
but declined in most recipients at 20–24 weeks post treatment.
Compared to transgenic DCs or DCs coated with a specific
immunodominant peptide (DC-pOVA), administration of as few
as 500 OVA-expressing HSCs into busulfan-pretreated animals
resulted in a maintenance of significantly higher frequencies of
OVA-specific cells at 4–16 weeks post immunization (Fig. 1C)
(p,0.03 for HSC-tOVA versus DC-pOVA and HSC-tOVA
versus DC-tOVA comparisons at 500 and 2610
4 HSC vaccine
doses at weeks 12 and 16). Pre-treatment of differentiated DC-
tOVA or DC-pOVA with LPS (bacterial lipopolysaccharide,
100 ng/ml, 24 hrs) or administration of DCs subcutaneously into
foot pad did not significantly enhance the longevity of induced
immune responses determined as frequency of antigen-specific
cells at weeks 4–16 post vaccination ([31] and data not shown).
Importantly, mice transplanted following myeloablative condition-
ing (lethal irradiation, 900 RAD) with 2610
4 HSCs displayed
significantly lower levels of frequencies of antigen-specific CD8
+ T
cells throughout the observation period (Fig. 1C).
Following transplantation, hematopoietic cells expressing non-
self antigen are continually removed by host’s cellular responses. To
address the relationship between the level of engrafted antigen-
expressing cells and resulting antigen-specific CD8
+ T cell
responses, B6 mice (CD45.2
+) were treated with a single dose of
BU or exposed to varying levels of radiation. Two days after BU
treatment or at the day of irradiation, respectively, mice were
administered with an equal number (10
4) of HSC-tOVA (B6
background, CD45.2
+) and normal HSCs from SJLmice(CD45.1
+)
(Fig. 2). Under these conditions, only OVA-expressing hematopoi-
etic cells derived from HSC-tOVA are targeted by host’s CTLs
while the SJL-derived hematopoietic cells are not recognized by
recipient’s immune system and can serve to determine the relative
level of engraftment. The levels of hematopoietic chimerism and the
frequencies of antigen-specific CD8
+ T cell responses were
determined in blood at 2 to 12 weeks post transplantation. While
untreated mice and BU-pretreated mice displayed less than 0.2%
chimerism, radiation-treated mice displayed gradually increasing
levels of chimerism up to 80% in lethally irradiated (900 RAD) mice
(Fig. 2B). Increasing level of chimerism inversely correlated with the
frequencies of antigen-specific CD8
+ cells (Fig. 2C and
D)(p=0.0002 and 0.008 at weeks 4 and 12, respectively). Optimal
maintenance of high levels of antigen-specific T cell responses
appears to be achieved under nonmyeloablative conditioning (BU
or 200 RAD) resulting in a low level of engraftment (,0.2% of
transgenic cells of total PBMCs).
In a series of analogous experiments, HSC-tOVA (CD45.2
+)
were transplanted into SJL (CD45.1
+) mice following various pre-
conditioning methods. No CD45.2
+ leukocytes were detectable in
recipients by flow cytometry above the background of the assay
(approximately 0.02% of total leukocytes). Similarly, OVA-
transgenic mice were crossed to SJL background and resulting
HSC-tOVA expressing CD45.1
+ were transplanted into B6
(CD45.2
+) recipients. No OVA-expressing CD45.1
+ leukocytes
were detectable in recipient animals by flow cytometry analysis
(data not shown). These experiments strongly suggest that antigen-
expressing cells are rapidly depleted by recipient’s immune system.
CD8
+ T cells maintained in recipients of transgenic HSCs
develop central memory T cell phenotype
While functional effector memory T cells mediate clearance of
tumor and infected cells in vivo, central memory T cells appear to
play an indispensible role in the long-term control [1,32]. To
investigate the phenotype of CD8
+ T cells elicited by HSC-tOVA
immunization, splenic OVA-specific CD8
+ T cells were analyzed
at 2, 4, 12, and 16 weeks following transplantation of 2610
4 HSC-
tOVA into BU-pretreated animals. At 2 to 4 weeks post
transplantation, antigen-specific CD8
+ T cells were distributed
between central memory (CD62L
+ CD27
+) effector memory
(CD62L
2 CD27
+), and, to a lesser degree, effector (CD62L
2
CD27
2) T cell populations (Fig. 3). At 16 weeks, more than 70%
of OVA-specific CD8
+ T cells displayed central memory
phenotype. Low production of IL-2, IFN-c, and granzyme B by
OVA-specific memory CD8
+ T cells harvested at 12 weeks post
immunization was observed by intracellular staining assay
following 6 hrs of ex vivo stimulation with specific OVA-1 peptide
(data not shown). This observation may be related to the constant
antigen stimulation of antigen-specific T cells in vivo.
Antigen-specific T cells induced by immunization with
HSC-tOVA efficiently kill target cells in vivo
To test the functionality of antigen-specific T cells induced by
administration of HSC-tOVA, the animals were immunized as
HSCs Induce Prolonged Cytotoxic T Cell Responses
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16897Figure1. Transplantation ofgeneticallymodified HSCs following nonmyeloablative conditioningresults in a prolongedmaintenance
ofantigen-specific CD8
+ Tcells. (A)B6 mice were immunizedi.v.with 10
5 DCsfromOVA-transgenicmice (DC-tOVA, left panel)or pretreatedwith BU
(60 mg/ml) and two days later transplanted with 2610
4 OVA-expressing HSCs (HSC-tOVA, right panel). Percentages of OVA-specific CD8
+ T cells out of
total CD8
+ leukocytes were determined in blood of immunized animals at the indicated time points by staining with OVA-specific MHC-I pentamer and
flow cytometry analysis. (B) Examples of flow cytometry analysis of OVA-specific CD8
+ T cell immune responses in blood of two representative animals.
(C) Mice were immunized with 500 or 2610
4 DC-tOVA, immunodominant OVA peptide-coated DCs (DC-pOVA), or HSC-tOVA following BU pretreatment
andthepercentagesof OVA-specificCD8
+ T cellsoutoftotal CD8
+ cells in bloodwere determined by OVA-specificMHC-Ipentamer stainingatindicated
time points. Mice in the HSC-tOVA/RAD group were exposed to a split dose of 900 RADs prior to transplantation of 2610
4 HSC-tOVA. 4 animals per
group; error bars represent standard errors. Representative results of two of five similar experiments are presented.
doi:10.1371/journal.pone.0016897.g001
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immunized animals and controls were administered with 10
7
CFSE-labeled splenocytes expressing OVA (Fig. 4A, high intensity
peak on the right). As internal control, 10
7 splenocytes from
normal B6 mice labeled with low concentration of CFSE were co-
injected (Fig. 4A, middle peak). Under these conditions, only
splenocytes from OVA-transgenic mice (right peak) will be
recognized by recipient’s OVA-specific CTLs. 24 hours after
injection, splenocytes were harvested and the number of
remaining CFSE
+ cells was determined. The groups administered
with 500 or 2610
4 HSC-tOVA under nonmyeloablative condi-
tions exhibited significantly greater extent of in vivo target cell
killing than mice immunized with OVA-transgenic (DC-tOVA) or
OVA peptide-coated DCs (Fig. 4B) (DC-pOVA) (p,0.05 for
HSC-tOVA/DC-pOVA and HSC-tOVA/DC-tOVA compari-
sons at both 500 and 2610
4 HSC vaccine doses). In contrast, mice
that received high dose of radiation (900 RAD) prior to the
transplantation of HSC-tOVA did not exhibit any detectable CTL
activity. Thus, high-level expression of antigen not only decreases
the frequency of antigen-specific CD8
+ T cells but also abrogates
antigen-specific cytotoxic activity.
Immunization with transgene-expressing HSCs results in
a protection against a model tumor
To test the ability of HSC-based immunization to protect
against tumor growth, mice were immunized with 2610
4 HSC-
tOVA or DCs presenting dominant MHC-I-restricted OVA
peptide and 16 weeks later challenged with 10
6 E.G7 thymoma
tumor cells expressing OVA antigen administered subcutaneously.
While antigen-specific CD8
+ T cells were maintained only at low
frequencies in DC-immunized animals, immunization with HSCs
resulted in an efficient maintenance of specific CTLs up to the
time of tumor challenge at week 16 (Fig. 5A). Mice immunized
with OVA-transgenic HSCs were able to control tumor growth
throughout the observation period significantly better than DC-
immunized or control group (Fig. 5B) (p,0.05 and p,0.001
between HSC-tOVA and DC-pOVA and HSC-tOVA and
control group, respectively, weeks 24–28; analyzed by RM-
ANOVA). At week 28, two of four HSC-OVA immunized mice
but only one of four DC-pOVA-immunized and none of four
control mice were free of palpable tumor.
Multiple hematopoietic lineages may contribute to the
induction of antigen-specific CD8
+ T cells in
HSC-immunized animals
Specific T cell responses in HSC-OVA recipients can be
induced either directly by transgene-expressing professional
Figure 2. Low level engraftment of transgenic HSCs is required
for elicitation of high frequencies of antigen-specific CD8
+ T
cells. (A) Experimental design. Recipient B6 mice (CD45.2
+) were not
treated, treated with BU, or exposed to varying levels of radiation as
described in Methods. 10
4 HSC-tOVA from OVA-transgenic mice on B6
background (CD45.2
+) and 10
4 HSCs from SJL mice (CD45.1
+) were co-
administered into the B6 recipients. (B) Percentages of chimerism
detected in the blood of recipient animals at indicated time points (4
mice per group). In some instances total values do not amount to 100%
due to the presence of cells falling into the CD45.1
2CD45.2
2 and
CD45.1
+CD45.2
+ populations. (C) Percentages of OVA-specific CD8
+ T
cells in blood determined by OVA-specific MHC-I pentamer staining at
indicated time points. (D) Inverse correlation between the level of
engraftment and induction of antigen-specific CD8
+ T cells (week 12
post HSC transplantation; analyzed by Spearman rank order correlation
test).
doi:10.1371/journal.pone.0016897.g002
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mechanism. To address the mechanism of specific T cell
induction, naı ¨ve mice were immunized i.v. with 2610
4 cells
representing individual populations purified from OVA-transgenic
mice. Immunization with DCs, B cells, NK cells, and cells of
macrophage/monocyte lineage, but not T cells, induced detect-
Figure 3. Antigen-specific CD8
+ T cells maintained in HSC-immunized recipients predominantly display central memory
phenotype. 2610
4 HSC-tOVA cells were transplanted into BU-conditioned B6 mice. OVA-specific CD8
+ T cells were detected in splenocytes of
immunized mice by staining with OVA-specific pentamer and anti-CD8 antibody. Percentages of antigen-specific CD8
+ T cells displaying central
memory (CD62L
+ CD27
+) effector memory (CD62L
2 CD27
+), or effector T cell (CD62L
2 CD27
2) phenotypes were determined in the spleens of
recipient animals at 2, 4, 12, and 16 weeks post transplantation. Data obtained in two animals per time point are presented.
doi:10.1371/journal.pone.0016897.g003
Figure 4. Antigen-specific T cells induced by HSC immunization efficiently kill target cells in vivo. (A) B6 mice were immunized with
2610
4 DC-tOVA, OVA peptide-coated DCs (DC-pOVA), or HSC-tOVA. HSC-tOVA recipients were pretreated with BU or irradiated with 900 RAD. 16
weeks post immunization, mice were injected with 10
7 OVA-transgenic splenocytes labeled with high concentration of CFSE (3.5 mM, right peak) and
10
7 wild type B6 splenocytes labeled with low concentration of CFSE (0.35 mM, middle peak). Under these conditions, only the splenocytes from OVA-
transgenic mice (right peak) are target of host OVA-specific CTLs. 24 hours post injection, splenocytes were harvested and the relative proportions of
remaining CFSE
+ populations were determined. (B) Graphical representation of the percentage of target cell killing in vivo. 4 animals per group; error
bars represent standard errors.
doi:10.1371/journal.pone.0016897.g004
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(Fig. 6). However, in the absence of hematopoietic precursors,
immune response subsided by 4 to 8 weeks post immunization.
Discussion
This study assessed whether administration of antigen-express-
ing HSCs under nonmyeloablative conditions induces and
maintains functional antigen-specific CTL responses for a
significantly longer period of time than that typically achieved
following immunization with peptide-loaded or antigen-expressing
DCs. We demonstrate that transplantation of low numbers of
genetically modified HSCs under nonmyeloablative or mildly
myeloablative conditions elicits and maintains long-term antigen-
specific CD8
+ T cell responses capable of killing target antigen-
expressing cells in vivo. High levels of functional CTLs were
readily detectable for 4 months post HSC transplantation and
display both effector and central memory phenotypes. HSC-based
immunization provided a significant control of the growth of a
model tumor in a preventive setting at four months post
immunization. To our knowledge, this is the first report
demonstrating efficient immunization with antigen-encoding
HSCs without a need of a simultaneous transfer of TCR-
transgenic T cells and/or complex in vivo stimulation with DC-
activating agents such as GM-CSF and CpG. As nonmyeloablative
conditioning is increasingly used for the treatment of oncologic
disorders [33–36,37], our observations may contribute to the
development of novel immunotherapeutic strategies for cancer
and therapeutic immunization against some chronic infectious
diseases such as HIV-1/AIDS.
Since mobilized peripheral blood-derived CD34
+ HSCs can be
efficiently transduced by lentiviral vectors [38,39], we believe that
genetically modified HSCs can be used as a basis for novel cellular
vaccine-based strategies. In contrast to TCR-based strategies, the
strategy presented here is independent of the MHC haplotype of
the patient; thus, the same lentiviral construct encoding common
tumor-associated antigen can be used in all potential recipients.
However, the efficacy and safety of HSC-based immunization
strategies need to be further evaluated in detailed studies prior to
their implementation to clinical practice. Importantly, it remains
to be established whether the proposed immunization strategy
would efficiently reverse the growth of an established tumor in a
therapeutic setting. Results of recently conducted clinical trials
employing transplantation of ex vivo-modified HSCs and
recombinant lentiviral vectors provide reasons for optimism
regarding the safety of this approach [15,16,18]. A number of
recent clinical trials have demonstrated that HSCs can be
modified safely with the current generation of self-inactivating
lentiviral vectors and transferred to recipients without elicitation of
adverse effects [17–19]. The ability of genetically modified HSCs
to maintain antigen-specific responses may be further enhanced by
targeting antigen expression to specific subsets of antigen-
presenting cells by utilization of lineage-specific promoters. In
Figure 5. Immunization with genetically modified HSCs results in protection against a growth of a model thymoma. Mice were
immunized with 2610
4 HSC-tOVA cells following BU pre-treatment or 2610
4 immunodominant OVA peptide-coated DCs. (A) Percentages of OVA-
specific CD8
+ T cells in blood were monitored by OVA-specific MHC-I pentamer staining. (B) 16 weeks post immunization, mice were inoculated s.c.
with 10
6 E.G7 thymoma cells expressing OVA. Tumor growth was monitored until mice became moribund. 4 animals per group; error bars represent
standard errors.
doi:10.1371/journal.pone.0016897.g005
Figure 6. Various hematopoietic lineages likely contribute to
the induction of antigen-specific CD8
+ T cells. Cell populations
representing indicated hematopoietic lineages were isolated from the
spleen and lymph nodes of OVA-transgenic mice by a combination of
magnetic column purification and flow cytometry sorting as described
in Methods. B6 mice were immunized i.v. by a single injection of 2610
4
cells of the indicated lineage and the percentage of OVA-specific CD8
+
T cells in blood was determined by pentamer staining at 2, 4, and 8
weeks post immunization. 3 animals per group; error bars represent
standard errors.
doi:10.1371/journal.pone.0016897.g006
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express the alloantigen and therefore are likely to be targeted by
recipient’s CTLs. Restricting antigen expression to differentiated
hematopoietic population such as DCs may significantly enhance
the half-life of transplanted HSCs and further prolong the
immunization effect.
Current strategies for T cell-based cancer immunotherapy have
been selected based on their ability to rapidly expand tumor-
specific T cells in vivo. However, accumulated data suggest that a
single expansion of large quantities of T cells is not sufficient to
sustain objective anti-tumor responses in cancer patients
[1,6,7,40]. Immunization with high doses of antigen in an
environment providing strong costimulatory signals, such as
following immunization with activated DCs or recombinant
viruses, favors rapid proliferation and differentiation of T cells
into Teff cells and ultimately T cells displaying an exhausted
phenotype [1,41]. Successful immunotherapy of cancer requires
multiple immunizations over prolonged periods of time to
maintain a functional effector T cell population [1,8,42,43].
Suboptimal induction of low frequencies of T cells displaying
effector phenotype results in a short-term effect and contributes to
the limited efficacy of cellular vaccine-based cancer immunother-
apy regimens.
Selective generation of central or early effector memory T cells
has been shown in both viral and tumor models to confer superior
protective and therapeutic immunity compared to Teff cells
[32,44–47]. Several recent reports have shown that in chronic
viral infections fully differentiated virus-specific T cells need to be
continually replaced by newly primed T cells recently generated in
thymus [48,49]. Newly primed T cells are phenotypically distinct
from exhausted T cells and display less differentiated phenotype
characterized by higher expression of CD62L, CD27, anti-
apoptotic protein bcl-2 and cytokines such as TNF-a and IL-2.
This process, at least partially dependent on a functional thymus,
prevents the decline of antigen-specific T cells and explains the
dependence of T cell ‘‘memory’’ on antigen in chronic infections
[50]. Successful T cell-based therapies should aim at continuous
induction of central memory/effector T cells at sites distant from
the immunosuppressive environment of tumor and draining lymph
nodes to avoid immune evasion and induction of tolerance. Since
the data presented here suggests that HSC-based immunization
results in a prolonged preservation of central memory CD8
+ T cell
responses induced systemically, HSC-based immunotherapy
appears to be a highly promising novel approach to CTL-based
immunotherapy.
Several previously published reports have addressed the
potential application of immunization with genetically modified
HSCs [20–22]. However, measurable immune responses and
control of tumor growth were achieved only by an adoptive
transfer of antigen-specific transgenic T cells and co-administra-
tion of anti-CD40, Flt3, GMCSF and/or CpG. Application of
such complex strategies in clinical setting would be associated with
a significant risk and low cost effectiveness. It is likely that HSC
transplantation into lethally irradiated recipients in the above cited
studies resulted in an induction of central and/or peripheral T cell
tolerance. In this regard, our data suggest that transplantation of
antigen-expressing HSCs under myeloablative conditions allowing
transgenic HSCs to populate a large percentage of the recipient’s
bone marrow results in a low frequency of antigen-specific T cells
(Fig. 1, 2). Moreover, elicited T cells are unable to kill target
antigen-expressing cells in vivo (Fig. 4). This phenomenon is
consistent with previously published studies [51–54]. The
mechanism of tolerance induction by HSC transplantation into
fully myeloablated recipients was addressed by Chan et al. who
demonstrated that transplantation of bone marrow genetically
modified to express myelin oligodendrocyte glycoprotein (MOG)
prevented the induction and progression of experimental autoim-
mune encephalomyelitis (EAE) and induced long-term remission
of established disease [52]. The mechanism involved was identified
as clonal deletion with no evidence for induction of antigen-
specific regulatory T cells. Similarly, using the OVA model, Dresh
et al. have demonstrated that a transplantation of bone marrow
cells genetically modified by lentiviral vector to express OVA
antigen under a control of a DC-specific promoter induced central
tolerance characterized by clonal depletion of antigen-specific
CD4
+ and CD8
+ T cells and T cell anergy indicated by the
inability of antigen-specific T cells to express TNF-a and IFN-c
and kill antigen-presenting target cells in vivo [51].
The appearance of antigen-specific T cells in recipients of
transgenic HSCs is delayed compared to animals immunized with
transgenic or peptide-coated DCs. This is consistent with the
appearance of circulating donor cells at 3–4 weeks post
transplantation as evidenced by the occurrence of chimerism in
CD45.2
+ controls transplanted with CD45.1
+ HSCs (data not
shown). This data is further corroborated by the results of Zhao et
al. who recently demonstrated that reconstitution of mice following
the transplantation of Lin
2 Sca-1
+ HSCs is delayed compared to
bone marrow transplantation and that first donor-derived DCs
occur in the spleen of recipient animals at 3 weeks post transplant
[22]. A significant decrease in the frequency of antigen-specific T
cells was consistently observed at 8 weeks post HSC transplanta-
tion followed by a rebound at 12 weeks. The mechanism
underlying this phenomenon is unclear. Recently, it has been
realized that purified Lin
2 Sca-1
+ c-kit
+ HSC population consist of
CD34
+ short-term reconstituting cells (STRCs) and CD34
2 self-
renewing long-term reconstituting cells (LTRCs) [28–30]. While
STRCs sustain clones of differentiating cells for only 4–6 weeks,
LTRM-derived hematopoietic cells persist for extended periods of
time. In light of these results, it is plausible that the kinetics of
appearance of specific T cell responses in HSC immunized
animals characterized by a peak at 4 weeks, contraction at 8
weeks, and a subsequent increase at 12–16 weeks post transplan-
tation is driven by the differential appearance of hematopoietic
cells derived from STRCs versus LTRCs. The reservoir of
dormant LTRCs was shown to be activated in response to
inflammation, stress, or injury signals [28–30]. This could partially
explain the high variability of OVA-specific CD8
+ T cell
frequencies observed in HSC-immunized mice at weeks 12–16
post transplantation.
The mechanism of induction and maintenance of specific T cell
responses in HSC-OVA recipients is unclear. Specific T cells can
be induced either directly by transgene-expressing professional
antigen presenting cells or indirectly by antigen cross-presentation
mechanism. The data presented on Figure 6 suggests that immune
responses in HSC recipient animals may be induced by multiple
cell lineages. In contrast to DCs, macrophages, and B cells known
as professional antigen-presenting cells, NK cells do not efficiently
present antigens to CD8
+ T cells. This result suggests that cells
derived from antigen-expressing HSCs may induce and maintain
specific T cells by a combination of direct antigen presentation and
cross-presentation mechanisms [55,56]. Along similar lines, we
have recently published a report demonstrating that efficient
immunization with antigen-expressing B cells likely depends on the
cross-presentation of the antigen [31]. However, the data
presented on Figure 6 do not directly prove an involvement of
any of the tested populations in specific T cell induction and more
detailed studies are warranted to fully understand the mechanism
of HSC-based immunization.
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HIV-1 infection, not a single patient has been successfully cured.
The only possible exception is a recipient of HSC transplantation
resulting in repopulation of CCR5-negative cells resistant to
infection with HIV-1 [37]. We have previously demonstrated that
therapeutic immunization of SIV-infected rhesus macaques with
CTL-inducing recombinant viral vaccines results in a partial
control of infection; however, antigen-specific CTLs expanded
following immunization rapidly decline to pre-vaccination levels
[3,12,13]. HSC immunization may be a promising strategy to
long-term maintenance of immune responses in therapeutically
immunized HIV-1-infected individuals simultaneously treated
with other regimens increasing their resistance to HIV-1 infection.
Important safety concerns need to be addressed before HSC-
based immunotherapy can be applied to clinical practice. More
research is warranted to address the interplay between the level of
HSC engraftment and the resulting induction of specific immune
responses versus tolerance. However, the data presented here
demonstrate the potential advantage of immunization with low
numbers of genetically modified HSCs over conventional DC-
based immunization and support application of immunization
with HSCs for the treatment and prevention of cancer and chronic
infectious diseases such as HIV-1/AIDS.
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